In phase 2 study of INO-5401 in combination with cemiplimab, Inovio Pharmaceuticals Inc (NASDAQ:INO) achieved success in ensuring the progression-free survival of patients who are diagnosed with GBM (glioblastoma multiforme). The phase 2 study is conducted using INO 9012, and INO 5401 in combination with a PD-1 blocking antibody – Libtayo on fifty-two patients diagnosed […]
Inovio Pharmaceuticals Inc (NASDAQ:INO)
Recent Posts
UAT Group Strategic Partner Next Casting Receives Patent
Livento Group announces the settlement of the promissory note and an equity investment
Franklin Mining Announced Letter to Shareholders and Investors
New Products, Growth – USMJ.com Memorial Day Sale
M2Bio Sciences Division M2Biome Cardiometabolic Health Launches Website
Popular Post
-
Hollywood Star Cuts Enters Into Acquisition Agreement!
-
FEED EARTH NOW (FEN) ANNOUNCES FOOD WASTE RECYCLING SYSTEM IN CALIFORNIA
-
Allied Enters into Gas Offtake Agreement with Sloan Petroleum to Procure Additional Natural Gas Wells for the Enerhash Bitcoin Mining Project
-
CGAC Completes $894,325 Purchase of 412 Bitcoin Miners, Mining Operations Underway
-
JPMorgan Bringing Back Employees to Work From Office
